about
Myeloid-derived suppressor cells as therapeutic target in hematological malignanciesDendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicNovel therapeutic strategies for multiple myelomaReview of health-related quality of life data in multiple myeloma patients treated with novel agents.Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.Immune checkpoint blockade for hematologic malignancies: a reviewDynamics of multiple myeloma tumor therapy with a recombinant measles virus.Lenalidomide enhances anti-myeloma cellular immunityGenetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsCD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL.Updates on osteonecrosis of the jawFOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT).Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agentsHow I treat smoldering multiple myeloma.Characterization of the Toll-like receptor expression profile in human multiple myeloma cells.Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cellsComparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeuticsAn antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.Drug-mediated and cellular immunotherapy in multiple myeloma.Immune alterations in untreated and treated multiple myeloma.Genetic variations in multiple myeloma II: association with effect of treatment.Genetic variations in multiple myeloma I: effect on risk of multiple myeloma.
P2860
Q27010234-51CC8CD7-9F83-45DD-910A-7202887EC0A1Q27023621-3B267434-99C5-4847-97F3-8AAD29E8C8B6Q28081590-4C6D972F-DF90-4BD1-BE9B-9E2F07300B3CQ30650394-CC86069D-0AC4-4D46-8498-86EC883C1868Q33479917-FFCBAA53-73F2-4304-9E16-B34DD1261F87Q33645590-8FAA4068-54E1-4D74-B601-474CDCDD5FAAQ33652517-D1DE29F1-B3C5-4098-BD83-6A4309244613Q33903133-A153FB05-D24F-426A-9206-BBE26461AF42Q33992425-74335567-DEDE-45BE-808A-A0C2B52E3B2AQ34095668-B13EF73F-DD02-4173-8889-75AB19E2CD2CQ34184457-7484B8F7-60B3-405B-ABC0-5717C769EC50Q34234108-37540854-943F-4057-8393-A0EAF9D2A562Q34402407-69021DC9-92C4-400D-B245-7AED35554500Q34436188-479287A3-DC55-48D7-A47C-E72F31CD63F4Q34447864-CF631007-0CAA-4232-A8D6-8F04E868ACBBQ34478019-D53AD677-F77F-43A2-8173-644666E5EF43Q34549211-FA44219E-73BE-40E0-8FB8-D23D00980D8BQ34580094-EBDA1E72-63DC-4692-A8CC-19F786FD63F4Q34673706-FD186AC2-52FC-484B-A3C7-277823456EEBQ34798105-754AD06F-37AC-4B90-A4E4-DAF85C4E1915Q34985537-68569CB1-ED5C-4693-ABC6-A92BAEC8E7A7Q35066433-83FFFE76-7087-47A5-9417-2A301A338524Q35669068-900923BC-7A8B-40F8-B2EF-B7FE2F27BC6EQ36065299-3C8A6B45-D29A-43F3-B3AB-2F6FF895911BQ36498366-DCD65B9D-1E5C-4EC6-A387-6CCED55E8E78Q36568780-260E13F9-955A-49AE-9810-5B9C76DC5717Q36718300-5DEB5755-EA42-41F1-AEF9-7C9CC83A3739Q36764389-9D713825-AC7C-46B6-8A77-8E6A3477E608Q36973705-D173EE58-448F-49E7-AAFA-931CCDEB68E7Q37029273-AF268706-5487-4B82-BA78-A958E731439EQ37233276-5B49F553-607D-4464-BDB1-B0A4D26D13A3Q37353007-3BD75DD2-16FE-4371-B445-910EE2163D7CQ37390723-B1652ABA-7E36-42A1-A592-36C671F410CEQ37517482-EABEBBD0-A20B-4711-B0A8-7575DF6180D4Q37609434-790B24F7-5CBA-4F06-9AB8-BDFF34E79689Q37737802-AFE4FC69-D11F-475C-BFCE-E2DACF1408A2Q37773257-645F2741-80B3-49D2-A7E6-3CB9F2596AA3Q37920966-7A27667E-1159-40FC-8028-DA29F3B47B3EQ37924890-1612FAE3-A807-4808-BC27-3573AFCD55B9Q37924891-B84F977E-F312-46B9-B730-28CE8BC4E9EA
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunodeficiency and immunotherapy in multiple myeloma.
@en
type
label
Immunodeficiency and immunotherapy in multiple myeloma.
@en
prefLabel
Immunodeficiency and immunotherapy in multiple myeloma.
@en
P2093
P2860
P1476
Immunodeficiency and immunotherapy in multiple myeloma.
@en
P2093
Oliver Goodyear
P2860
P304
P356
10.1111/J.1365-2141.2007.06705.X
P407
P577
2007-09-01T00:00:00Z